Bioenvision Inc.

Dr. Christopher B. Wood has served as the Chairman and Chief Executive Officer of Bioenvision since January 1999. From January 1997 to December 1998, Dr. Wood was chairman of Eurobiotech, Inc.

Andrew Saunders, M.D. has served as Medical Director at Bioenvision since May 2005. Dr. Saunders joined us from Global Drug Development at Hoffman-La-Roche where he was Clinical Science Leader for MabThera oncology with global medical and scientific responsibility for the MabThera development programme. From 2000 to 2002, Dr. Saunders held the position of European Clinical Research Physician in oncology with Eli Lilly & Company. Dr. Saunders holds a Degree in Medicine (1989) from Trinity College Dublin, Republic of Ireland including primary degree qualifications as follows: Batchelor of Medicine; Batchelor of Surgery; Batchelor of Obstetrics; Batchelor of Arts. Dr. Saunders underwent post-graduate training in general medicine and haematology and his Post-Graduate qualifications include: MRCP (Member of Royal College of United Kingdom) in 1996; and MFPM (Member of Faculty Pharmaceutical Medicine) in 2000.

Keith Gillon joined Bioenvision in March 2005 as Director of Product Development. Prior to joining Bioenvision, Dr. Gillon was a consultant to the pharmaceutical industry from March 2003 until February 2005 during which he specialised in advanced methodology for patient recruitment for clinical trials and established a state of the art clinical research centre in the UK. Previously, he managed the Clinical Services Division for Quintiles Scotland and led Quintiles' patient recruitment company, Minerva Medical, specialising in large, phase III trials from October 1998 to February 2003. Dr. Gillon has worked at several major pharmaceutical companies including Astra Pharmaceuticals, where his responsibilities included programme management of international studies in gastroenterology and cardiology and Pfizer, where he served as Clinical Project Manager for diabetes and was responsible for a pan-European clinical programme. Dr Gillon has a Bachelor of Science Honours degree and PhD in Biochemistry.

Mr. Luci joined MacroChem in December 2007 as General Counsel and VP Corporate Development. In addition, in March 2008, Mr. Luci was appointed Chief Financial Officer. In April 2008, he was appointed President and Chief Business Officer and in this capacity, assumed the responsibilities of Chief Operating Officer and continued his responsibilities as Chief Financial Officer and General Counsel. Prior to joining MacroChem, Mr. Luci served as Executive Vice President, General Counsel & Corporate Secretary of Bioenvision (Nasdaq: BIVN) where he created and managed the company's offices in New York, raised over $100 million in capital, and advanced Bioenvision's stock listing from OTC BB to AMEX and then to NASDAQ. He was also responsible for garnering sell-side analyst coverage initiated by a number of investment banking firms including JP Morgan, UBS, CIBC World Markets, Oppenheimer & Rodman & Renshaw, each while serving as Bioenvision's Chief Financial Officer. While at Bioenvision, he was responsible for in-licensing the rights to the company's lead cancer drug for development and marketing in Japan and Southeast Asia and initiated drug development activities in Japan. He later successfully guided Bioenvision into a merger agreement and closing of a related tender offer with its U.S. co-development partner, Genzyme Corporation, in a transaction valued at approximately $345 million. Prior to joining Bioenvision, Mr. Luci practiced securities law and mergers and acquisitions at Paul, Hastings, Janofsky and Walker LLP, New York from 1994 to 2002. Prior to Paul Hastings, he was Senior Auditor, Ernst and Young, New York from 1988 to 1991, focused on internal audit and controls within the Mergers and Acquisitions Practice Group. He is also a member of the Board of Directors and Chairman of the Audit Committee and Compensation Committee of Access Pharmaceuticals, Inc. Mr. Luci received his JD, cum laude, from Albany Law School of Union University and his Bachelor of Science in Business Administration with a concentration in accounting from Bucknell University. He is a member of the New York State Bar Association and earned certification as a Certified Public Accountant (Pennsylvania) in 1991.

Michael Kauffman joined as a member of our board of directors in June 2006. Dr. Kauffman joined Predix Pharmaceuticals, Inc., the predecessor to EPIX, in September 2002. Prior to that he held a number of senior medical and program leadership positions at Millennium Pharmaceuticals Inc., including Vice President, Medicine and VELCADE Program Leader as well as co-founder and Vice President of Medicine at Millennium Predictive Medicine, a wholly-owned subsidiary of Millennium. Dr. Kauffman also served as Medical Director at Biogen Corporation (now Biogen Idec). Dr. Kauffman currently serves on the board of directors for Bioenvision, a publicly traded biopharmaceutical company. Dr. Kauffman received his MD and Ph.D. in molecular biology and biochemistry at Johns Hopkins and his BA in biochemistry summa cum laude from Amherst College. He trained in Internal Medicine at Beth Israel Deaconess and Massachusetts General Hospitals. He is board certified in internal medicine.